Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

Belantamab mafodotin-blmf (Blenrep), combined with pomalidomide (Pomalyst) and dexamethasone (BPd), demonstrated a higher percentage of patients achieving meaningful improvements compared with ...

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even the ...

Japan's Ministry of Health, Labour and Welfare has also granted Blenrep orphan drug designation, which GSK said "reflects the high unmet medical need and ensures priority NDA review in multiple ...

While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...

NEWS ANALYSIS: Norwegian Prime Minister Jonas Gahr Støre was quick to congratulate Donald Trump on Wednesday, even before the final vote in the US presidential election was tallied. Støre stressed ...